Tesamorelin: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Structured Community Data
- โขBased on 100 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Approved Indication vs Community Use | Tesamorelin is FDA-approved (as Egrifta) specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials were conducted exclusively in this population at 2 mg daily. | Community uses tesamorelin off-label for general visceral fat reduction, body composition, anti-aging, and cognitive benefits. Users are typically non-HIV individuals seeking fat loss or GH optimization. | high The off-label use in non-HIV populations is the primary community application, but clinical efficacy data is specific to HIV lipodystrophy. Results may differ in metabolically healthy individuals. |
| Source and Formulation | Clinical trials used pharmaceutical-grade Egrifta (tesamorelin for injection) or the newer Egrifta WR formulation. These are manufactured under strict GMP conditions. | Some community members use prescription Egrifta from pharmacies while others source tesamorelin from research peptide vendors or compounding pharmacies. Product quality varies significantly by source. | high Pharmaceutical Egrifta is well-characterized but expensive. Research-grade tesamorelin may vary in purity and potency. Users should be aware of quality differences between sources. |
| Treatment Duration | Pivotal clinical trials ran for 26 weeks, with extension studies up to 52 weeks. Fat rebound occurred after discontinuation in clinical data. | Community members typically run 12-16 week cycles. Some use ongoing maintenance protocols. Awareness of fat rebound after stopping varies. | moderate Clinical data shows visceral fat reduction reverses after stopping tesamorelin. Community protocols are often shorter than clinical trials. |
Compare these community approaches with published research findings.
Community Protocols
Standard Fat Loss Protocol
Popular- Route
- Subcutaneous
- Dose
- 2 mg
- Frequency
- Once daily
- Duration
- 12-26 weeks
FDA-approved dose for HIV lipodystrophy; adopted by community for general visceral fat reduction. Injected in abdominal area before bed.
Beginner/Conservative Protocol
Common- Route
- Subcutaneous
- Dose
- 1 mg
- Frequency
- Once daily
- Duration
- 12-16 weeks
Half the standard dose; used by new users to assess tolerance before potentially increasing to 2 mg
Maintenance Protocol
Common- Route
- Subcutaneous
- Dose
- 1-2 mg
- Frequency
- 5 days per week
- Duration
- Ongoing with periodic breaks
Reduced frequency for long-term use; some users find 5 days on, 2 days off sufficient to maintain results
Tesamorelin + Ipamorelin Stack
Niche- Route
- Subcutaneous
- Dose
- 1-2 mg tesamorelin + 200 mcg ipamorelin
- Frequency
- Once daily before bed
- Duration
- 12-16 weeks
Combines GHRH analog with GHRP for enhanced GH output; less common due to tesamorelin cost
Stacking Patterns
Tesamorelin + Ipamorelin
CommonCombines FDA-approved GHRH analog with selective GHRP for enhanced GH pulse amplitude; tesamorelin provides potent GHRH stimulation while ipamorelin adds ghrelin pathway activation
Tesamorelin + CJC-1295 DAC
NicheDual GHRH approach; some users alternate between the two rather than combining, using tesamorelin daily with periodic CJC-1295 DAC injections
Tesamorelin + AOD-9604 Fat Loss Stack
NicheCombined approach to fat reduction; tesamorelin for GH-mediated visceral fat reduction and AOD-9604 for additional lipolytic activity
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 100+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|Tesamorelin experience reports and fat loss discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|Tesamorelin protocol and visceral fat reduction threads(accessed 2026-02-16)
- Swolverine|Tesamorelin for Beginners (benefits, dosage, stacking tips)(accessed 2026-02-16)
- Innerbody|Tesamorelin Peptide Benefits, Safety, and Buying Advice (2026)(accessed 2026-02-16)
- Peptides.org|Tesamorelin Dosage Calculator and Chart(accessed 2026-02-16)
- PeptideDosages.com|Tesamorelin 10mg Vial Dosage Protocol(accessed 2026-02-16)
- Muscle and Brawn|Tesamorelin Peptide Guide (benefits, dosage, bodybuilding)(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Tesamorelin (Egrifta). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
Tesamorelin holds a unique position in the peptide community as one of the few FDA-approved GHRH analogs, lending it additional clinical credibility. However, its approval is specifically for HIV-associated lipodystrophy, and community use is overwhelmingly off-label for general fat loss and body composition improvement.
Understanding Protocol Divergence#
Approved vs Off-Label Use#
The most significant aspect of tesamorelin community use is the gap between its FDA-approved indication (HIV lipodystrophy) and its community application (general visceral fat reduction). Clinical trial participants were HIV-positive individuals with specific metabolic dysfunction, and results in metabolically healthy non-HIV individuals may differ.
Cost and Source Considerations#
Pharmaceutical-grade Egrifta is expensive, leading many community members to source tesamorelin from compounding pharmacies or research peptide vendors. This introduces variability in product quality that does not exist with the FDA-approved formulation.
Fat Rebound After Discontinuation#
An important finding from clinical trials that is not always emphasized in community discussions is that visceral fat reduction reverses after stopping tesamorelin. This has implications for community users who plan short cycles expecting permanent results.
Commonly Reported Outcomes#
Community members frequently report the following when using tesamorelin:
- Visceral fat reduction: The primary reported benefit, typically noticed at 6-8 weeks with significant reduction at 12-16 weeks
- Sleep quality: Improved sleep depth, often noticed within 1-2 weeks
- Skin quality: Some users report improvements in skin elasticity over several months
- Cognitive function: Some users report improved mental clarity, aligned with published cognitive research
- Body composition: Overall improvement in body composition beyond isolated fat loss
Important Caveats#
- Off-label use in non-HIV populations lacks robust clinical data
- Visceral fat reduction reverses after discontinuation
- Product quality varies significantly between pharmaceutical and research-grade sources
- Tesamorelin is expensive, making it less accessible than other GH secretagogues
- Self-reported outcomes lack objective measurement controls
Reconstitution and Storage Practices#
Community reconstitution practices for tesamorelin:
- Reconstitution: Follow specific vial instructions; pharmaceutical Egrifta has its own diluent
- Research-grade: 1-2 mL bacteriostatic water per vial
- Storage: Reconstituted solution refrigerated at 2-8 degrees C
- Shelf life: Use reconstituted solution within 2-3 weeks
- Injection site: Abdominal subcutaneous fat, rotating injection sites
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Tesamorelin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.